GEN Exclusives

More »

GEN News Highlights

More »
Oct 11, 2007

Maas Biolab Awarded $2.1M to Enable Studies on Intrathecal Delivery of ALS Drug

  • Maas Biolab received an SBIR grant of $2.1 million to advance research on its drug candidate for amyotrophic lateral sclerosis (ALS). The National Institute of Neurological Disorders and Stroke grant extends over three years.

    The compound, known as Mitogard®, is a formulation of the direct mitochondrial neuroprotectant cyclosporine. It is the only cyclosporine compound designed for cerebrospinal fluid administration, according to Maas Biolab.

    The company believes that intrathecal delivery of Mitogard will overcome challenges faced by systemic cyclosporine, which does not easily reach the brain and spinal cord. Dose-escalation toxicology and pharmacokinetics safety studies will be performed by Northern Biomedical Research to enable IND approval for ALS clinical trials.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?